Edition:
United Kingdom

Precision Therapeutics Inc (AIPT.OQ)

AIPT.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
10 Aug 2018
Change (% chg)

-- (--)
Prev Close
$1.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,841
52-wk High
$2.50
52-wk Low
$0.81

Select another date:

Thu, May 10 2018

BRIEF-Precision Therapeutics Projects Meaningful Streamway System Sales In Europe In Second Half Of 2018

* PRECISION THERAPEUTICS PROJECTS MEANINGFUL STREAMWAY SYSTEM SALES IN EUROPE IN THE SECOND HALF OF 2018

BRIEF-Precision Therapeutics Signs Letter Of Intent To Purchase Remainder Of Helomics Corporation Shares

* PRECISION THERAPEUTICS, INC. SIGNS LETTER OF INTENT TO PURCHASE REMAINDER OF HELOMICS CORPORATION SHARES

BRIEF-Precision Therapeutics Q4 Loss Per Share $0.43

* PRECISION THERAPEUTICS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS

BRIEF-Precision Therapeutics Announces Record Streamway System Sales In The First Three Months Of 2018

* PRECISION THERAPEUTICS ANNOUNCES RECORD STREAMWAY® SYSTEM SALES IN THE FIRST THREE MONTHS OF 2018

BRIEF-Precision Therapeutics Unit Announces License Agreement With Cellbridge Inc

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED

BRIEF-Precision Therapeutics Subsidiary, Tumorgenesis, Announces License Agreement With 48Hour Discovery

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH 48HOUR DISCOVERY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Precision Therapeutics Unit, Tumorgenesis, Announces License Agreement With Syntarray LLC

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH SYNTARRAY, LLC

Select another date: